Apigenin protects mice from pneumococcal pneumonia by inhibiting the cytolytic activity of pneumolysin

Fitoterapia

Volumn 115, Issue , 2016, Pages 31-36

  Song, Meng ^a   Li, Li ^a   Li, Meng ^a   Cha, Yonghong ^a   Deng, Xuming ^a   Wang, Jianfeng ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Anti virulence; Apigenin; Pneumolysin; Streptococcus pneumoniae

Indexed keywords

APIGENIN; INTERLEUKIN 1BETA; OXACILLIN; PNEUMOLYSIN; TUMOR NECROSIS FACTOR; BACTERIAL PROTEIN; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; CELL DAMAGE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG PROTECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTECTION; STREPTOCOCCUS PNEUMONIA; A-549 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; PNEUMONIA, PNEUMOCOCCAL;

A549 CELLS; ANIMALS; APIGENIN; BACTERIAL PROTEINS; FEMALE; HEMOLYSIS; HUMANS; MICE; MICE, INBRED BALB C; PNEUMONIA, PNEUMOCOCCAL; STREPTOLYSINS;

EID: 84988949720     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2016.09.017     Document Type: Article

References (28)

1. [1] Gilley, R.P., Orihuela, C.J., Pneumococci in biofilms are non-invasive: implications on nasopharyngeal colonization. Front. Cell. Infect. Microbiol., 4, 2014, 163.
2. [2] Gray, B.M., Converse, G.M. 3rd, Dillon, H.C. Jr., Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J. Infect. Dis. 142:6 (1980), 923–933.
3. [3] Shewell, L.K., Harvey, R.M., Higgins, M.A., Day, C.J., Hartley-Tassell, L.E., Chen, A.Y., Gillen, C.M., James, D.B., Alonzo, F. 3rd, Torres, V.J., Walker, M.J., Paton, A.W., Paton, J.C., Jennings, M.P., The cholesterol-dependent cytolysins pneumolysin and streptolysin O require binding to red blood cell glycans for hemolytic activity. Proc. Natl. Acad. Sci. U. S. A. 111:49 (2014), E5312–E5320.
4. [4] Marks, L.R., Parameswaran, G.I., Hakansson, A.P., Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo. Infect. Immun. 80:8 (2012), 2744–2760.
5. [5] Ortqvist, A., Hedlund, J., Kalin, M., Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin. Respir. Crit. Care Med. 26:6 (2005), 563–574.
6. [6] Lynch, J.P. 3rd, Zhanel, G.G., Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16:3 (2010), 217–225.
7. [7] Kaur, R., Surendran, N., Ochs, M., Pichichero, M.E., Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae. Infect. Immun. 82:12 (2014), 5069–5075.
8. [8] Griffin, M.R., Zhu, Y., Moore, M.R., Whitney, C.G., Grijalva, C.G., U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N. Engl. J. Med. 369:2 (2013), 155–163.
9. [9] Brown, A.O., Millett, E.R., Quint, J.K., Orihuela, C.J., Cardiotoxicity during invasive pneumococcal disease. Am. J. Respir. Crit. Care Med. 191:7 (2015), 739–745.
10. [10] Weinberger, D.M., Malley, R., Lipsitch, M., Serotype replacement in disease after pneumococcal vaccination. Lancet 378:9807 (2011), 1962–1973.
11. [11] Lawrence, S.L., Feil, S.C., Morton, C.J., Farrand, A.J., Mulhern, T.D., Gorman, M.A., Wade, K.R., Tweten, R.K., Parker, M.W., Crystal structure of Streptococcus pneumoniae pneumolysin provides key insights into early steps of pore formation. Sci. Report., 5, 2015, 14352.
12. [12] Hook, E.W. 3rd, Horton, C.A., Schaberg, D.R., Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 249:8 (1983), 1055–1057.
13. [13] Feldman, C., Munro, N.C., Jeffery, P.K., Mitchell, T.J., Andrew, P.W., Boulnois, G.J., Guerreiro, D., Rohde, J.A., Todd, H.C., Cole, P.J., et al. Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo. Am. J. Respir. Cell Mol. Biol. 5:5 (1991), 416–423.
14. [14] Berry, A.M., Yother, J., Briles, D.E., Hansman, D., Paton, J.C., Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect. Immun. 57:7 (1989), 2037–2042.
15. [15] Harvey, R.M., Hughes, C.E., Paton, A.W., Trappetti, C., Tweten, R.K., Paton, J.C., The impact of pneumolysin on the macrophage response to Streptococcus pneumoniae is strain-dependent. PLoS One, 9(8), 2014, e103625.
16. [16] Park, S.A., Park, Y.S., Bong, S.M., Lee, K.S., Structure-based functional studies for the cellular recognition and cytolytic mechanism of pneumolysin from Streptococcus pneumoniae. J. Struct. Biol. 193:2 (2016), 132–140.
17. [17] Shak, J.R., Ludewick, H.P., Howery, K.E., Sakai, F., Yi, H., Harvey, R.M., Paton, J.C., Klugman, K.P., Vidal, J.E., Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of biofilms. MBio, 4(5), 2013, e00655-13.
18. [18] Hotomi, M., Yuasa, J., Briles, D.E., Yamanaka, N., Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization. Folia Microbiol., 2016, 1–9.
19. [19] Patil, R.H., Babu, R.L., Naveen Kumar, M., Kiran Kumar, K.M., Hegde, S.M., Nagesh, R., Ramesh, G.T., Sharma, S.C., Anti-inflammatory effect of apigenin on LPS-induced pro-inflammatory mediators and AP-1 factors in human lung epithelial cells. Inflammation 39:1 (2016), 138–147.
20. [20] Xu, M., Wang, S., Song, Y.U., Yao, J., Huang, K., Zhu, X., Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/beta-catenin signaling pathway. Oncol. Lett. 11:5 (2016), 3075–3080.
21. [21] Dong, J., Qiu, J., Wang, J., Li, H., Dai, X., Zhang, Y., Wang, X., Tan, W., Niu, X., Deng, X., Zhao, S., Apigenin alleviates the symptoms of Staphylococcus aureus pneumonia by inhibiting the production of alpha-hemolysin. FEMS Microbiol. Lett. 338:2 (2013), 124–131.
22. [22] Li, H., Zhao, X., Wang, J., Dong, Y., Meng, S., Li, R., Niu, X., Deng, X., Beta-sitosterol interacts with pneumolysin to prevent Streptococcus pneumoniae infection. Sci. Report., 5, 2015, 17668.
23. [23] Zhao, X., Li, H., Wang, J., Guo, Y., Liu, B., Deng, X., Niu, X., Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin oligomers. Mol. Pharmacol. 89:3 (2016), 376–387.
24. [24] Wang, J., Zhou, X., Liu, S., Li, G., Shi, L., Dong, J., Li, W., Deng, X., Niu, X., Morin hydrate attenuates Staphylococcus aureus virulence by inhibiting the self-assembly of alpha-hemolysin. J. Appl. Microbiol. 118:3 (2015), 753–763.
25. [25] Qiu, J., Niu, X., Dong, J., Wang, D., Wang, J., Li, H., Luo, M., Li, S., Feng, H., Deng, X., Baicalin protects mice from Staphylococcus aureus pneumonia via inhibition of the cytolytic activity of alpha-hemolysin. J. Infect. Dis. 206:2 (2012), 292–301.
26. [26] Wang, J., Qiu, J., Tan, W., Zhang, Y., Wang, H., Zhou, X., Liu, S., Feng, H., Li, W., Niu, X., Deng, X., Fisetin inhibits Listeria monocytogenes virulence by interfering with the oligomerization of listeriolysin O. J. Infect. Dis. 211:9 (2015), 1376–1387.
27. [27] Gilbert, R.J., Rossjohn, J., Parker, M.W., Tweten, R.K., Morgan, P.J., Mitchell, T.J., Errington, N., Rowe, A.J., Andrew, P.W., Byron, O., Self-interaction of pneumolysin, the pore-forming protein toxin of Streptococcus pneumoniae. J. Mol. Biol. 284:4 (1998), 1223–1237.
28. [28] Murrah, K.A., Pang, B., Richardson, S., Perez, A., Reimche, J., King, L., Wren, J., Swords, W.E., Nonencapsulated Streptococcus pneumoniae causes otitis media during single-species infection and during polymicrobial infection with nontypeable Haemophilus influenzae. Pathog. Dis., 73(5), 2015.